A familial Alzheimer's genetic panel is a blood test that looks for mutations in three genes — APP, PSEN1, and PSEN2 — known to cause early-onset Alzheimer's that runs in families. It's typically ordered during an Alzheimer's workup when a doctor sees a specific inherited pattern, costs roughly $300 to $1,000 depending on insurance, and requires a referral question most primary care doctors aren't equipped to sort out alone. Because this test sits at the intersection of clinical genetics, insurance policy, and family history, patients often get bounced between a memory clinic and a genetic counselor before anyone orders anything. Here's what determines whether the panel gets ordered at all, what it costs, what it can and can't tell you, and what to ask before you agree to it.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- When does a workup call for this panel?
- What does the panel actually cost?
- What can the test actually tell you?
- Will insurance pay for it, and who approves the referral?
- What about the counseling visit itself?
- Does a positive result affect other insurance?
- Frequently Asked Questions
When does a workup call for this panel?
The panel isn't offered to every Alzheimer's patient — it's reserved for a specific family pattern. The 2011 joint practice guideline from the American College of Medical Genetics and Genomics (ACMG) and the National Society of Genetic Counselors defines familial, autosomal dominant Alzheimer's as at least three affected relatives spanning two or more generations, with two of those three being first-degree relatives (parent, sibling, or child) of the third, according to the ACMG/NSGC joint practice guideline. That guideline recommends offering testing to two groups: someone with early-onset symptoms whose family history fits that three-generation pattern, or an asymptomatic relative of someone already confirmed to carry one of the three mutations.
A single relative with dementia, or a family history scattered with the more common late-onset form of Alzheimer's, doesn't meet the bar on its own. This distinction matters because it's the first thing a clinic checks before even discussing cost. If the family tree doesn't show the autosomal dominant pattern, the conversation usually shifts away from PSEN1/PSEN2/APP testing and toward other parts of the dementia workup instead.
What does the panel actually cost?
List pricing for the three-gene familial panel runs about $990 to $1,000 per order, based on published pricing from PreventionGenetics for its Familial Panel. That's the sticker price before insurance, financial assistance programs, or lab-specific discounts are applied.
Out-of-pocket reality looks different for most patients. A September 2025 presentation from the University of Wisconsin's genetic counseling program reported that real-world patient costs for dementia gene panels ranged from $0 to $1,000, but typically landed around $300, with results taking about three weeks to come back, according to the UW-Madison/DDCN presentation. The gap between list price and typical out-of-pocket cost comes down almost entirely to insurance coverage and whether the lab's financial assistance program applies.
- Ask the ordering clinic whether the lab has a maximum out-of-pocket cap for self-pay or underinsured patients.
- Ask whether the quoted price includes genetic counseling, or whether that's billed separately.
- Get the cost estimate in writing before blood is drawn — the three-week turnaround means there's no fast fix if the estimate turns out wrong.
What can the test actually tell you?
A positive result identifies a disease-causing mutation, but a negative result doesn't rule out familial Alzheimer's. ARUP Laboratories reports that its early-onset Alzheimer's sequencing panel finds a causative PSEN1, PSEN2, or APP variant in about 60% to 80% of genuinely familial early-onset cases, according to ARUP's August 2024 report. That leaves a meaningful share of families with a clear inherited pattern but no mutation found on this particular panel. Part of the gap is technical.
ARUP's panel detects variants in the coding regions of the genes and the boundaries between introns and exons, but it isn't built to catch every type of genetic change — so some causative mutations simply fall outside what the test can see. A negative result in a family that otherwise fits the autosomal dominant pattern means the mutation may be real but undetected, not that the family history is irrelevant. This is the reason genetic counseling typically happens before and after testing, not just after. Interpreting a negative result in a strongly affected family takes more context than the lab report alone provides.
Will insurance pay for it, and who approves the referral?
Coverage generally follows the same criteria used to decide whether testing is appropriate in the first place. A Blue Cross/Blue Shield of South Carolina medical policy treats PSEN1/PSEN2/APP testing as medically necessary for people with an autosomal-dominant early-onset family history, or for an asymptomatic first-degree relative of a confirmed carrier — but not for general screening outside those situations, according to the BlueCross BlueShield of South Carolina policy.
A 2026 Blue Shield of California Promise Medi-Cal policy follows a similar structure, requiring prior authorization and documented Alzheimer's-consistent symptoms for APOE testing, while covering targeted PSEN1/PSEN2/APP testing for asymptomatic at-risk relatives of a known carrier, according to the Blue Shield of California Promise policy. Medicare and Medicaid coverage tends to be narrower than commercial plans. A provider handout from the UCSF Memory and Aging Center instructs clinicians to have patients confirm genetic counseling and testing coverage directly with their insurer before ordering, specifically flagging that patients with Medicare or Medicaid as their primary payer may face limited coverage, according to the UCSF Memory and Aging Center handout.
- Confirm your plan's medical necessity criteria match your family history before the test is ordered, not after the bill arrives.
- If Medicare or Medicaid is your primary payer, ask explicitly about coverage for both the panel and any genetic counseling visit attached to it.
- A referral from a memory clinic or neurologist carries more weight with insurers than a request initiated without a documented family history.
What about the counseling visit itself?
Genetic counseling is billed separately from the lab test, and its billing rules changed recently. CPT code 96041 replaced the older 96040 for genetic counseling services effective January 1, 2025. Indiana Medicaid, for example, began separately reimbursing 96041 in the outpatient setting only for dates of service on or after April 1, 2025, while Medicare commonly bundles the code into another service rather than paying for it separately, according to an Indiana Medicaid bulletin.
A structural gap compounds this: genetic counselors currently cannot bill Medicare directly for counseling visits, because they lack Medicare provider status. The Access to Genetic Counselor Services Act (S.3607), introduced in the 119th Congress in 2025, would create that provider status under Part B, but it has not yet passed, according to the bill text on Congress.gov. In practice, this means a Medicare patient's counseling visit often has to be billed under the referring physician or folded into another service, which can affect whether it's covered at all.
Does a positive result affect other insurance?
A positive familial result carries protections, but not all of them. The federal Genetic Information Nondiscrimination Act (GINA) bars genetic discrimination in health insurance and employment decisions, but it explicitly does not extend to life insurance, disability insurance, or long-term-care insurance, according to the National Human Genome Research Institute's explanation of GINA.
That means a confirmed PSEN1, PSEN2, or APP mutation could still affect an application for one of those policy types. Anyone considering testing for themselves or an asymptomatic relative should weigh this before results come back — particularly if life or long-term-care coverage isn't already locked in. Genetic counselors routinely raise this point during pre-test counseling precisely because it's not protected by the same law that covers health insurance and employment.
Frequently Asked Questions
Can a negative genetic test rule out familial Alzheimer's in my family?
No. ARUP Laboratories finds a causative PSEN1, PSEN2, or APP mutation in only about 60% to 80% of genuinely familial early-onset cases, and the panel doesn't detect every type of genetic change, so a negative result in a strongly affected family doesn't rule out an inherited mutation.
Does a positive result affect my existing health insurance?
No. GINA bars health insurance and employment discrimination based on genetic results, but it does not cover life, disability, or long-term-care insurance, so those policy types can still be affected.
Who typically qualifies for insurance-covered testing?
Insurers generally require either early-onset symptoms fitting an autosomal dominant family pattern — three affected relatives across two generations — or asymptomatic status as a first-degree relative of someone already confirmed to carry one of the three mutations.
